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Case presentation
The patient is a 55-year-old white male with dilated cardiomyopathy
and severe congestive heart failure, New York Heart Association class
IV. He remained symptomatic and failed to diurese following maximal
treatment with afterload reduction and furosemide (320 mg/day). After
giving informed consent, he was taken to the cardiac catheterization
laboratory for hemodynamic and renal functional monitoring to assess
the possible beneficial effect of a 2-hour infusion of 0.1 g/kg/min of
synthetic human atrial natriuretic peptide (ANP). The baseline, pre-
infusion plasma ANP concentration was tenfold elevated above normal
(330 pg/mI) and was further increased to 3000 pg/mi by exogenous ANP.
The ANP infusion produced salutary effects on pulmonary capillary
wedge pressure (25 to 15 mm Hg) and systemic vascular resistance
(1800 to 1375 dyne/sec cm—5). Cardiac performance improved, with a
peak increase in cardiac index of 25% (2.0 to 2.5 liter/min/m2). Mean
arterial pressure declined somewhat (88 to 82 mm Hg) without produc-
ing an accompanying change in heart rate (88 to 86 beats/mm). Although
ANP augmented cardiac function and reduced by approximately 50%
the elevated levels of circulating renin, aldosterone, and norepineph-
rifle, the preexisting abnormalities in renal function were little affected.
Infusion of ANP caused little amelioration of either the intense anti-
natriuresis (urinary sodium excretion 30 to 50 Eq/min) or glomerular
hypofiltration (inulin clearance 82 to 85 mI/mm). When the ANP
infusion was discontinued, hemodynamic and renal parameters re-
turned to preexisting values within one hour.
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Discussion
DR. MARTIN G. COGAN (Chief, Nephrology Section, Veter-
ans Administration Medical Center, and Associate Professor of
Medicine, University of California, San Francisco, California):
The existence of granules in the cardiac atria has been known
for several decades [1]. The atria also have long been recog-
nized to be involved in the afferent signaling pathway by which
the kidney adjusts sodium excretion in response to changes in
extracellular volume [2, 3]. Yet the discovery of atrial natri-
uretic peptide (ANP) awaited the ingenious, surprisingly simple
experiments of DeBold and coworkers published in 1981 [4]. In
the subsequent decade, an explosion in research has occurred,
especially following the sequencing and synthesis of ANP. In
part, basic science interest in ANP derives from its unique
receptor-signal transduction system. From a physiologic stand-
point, the fascination with ANP can be explained historically.
Endogenous natriuretic substances have been postulated to
exist for many years and have been invoked to interpret many
phenomena, such as mineralocorticoid escape, that have eluded
explanation based on conventional neurohumoral mechanisms
[51.
Due to the enormous outpouring of research (currently more
than 900 papers per year), this review will necessarily be a
summary, with special emphasis on the mechanism of action
and physiologic importance of ANP in controlling renal sodium
handling in humans. Other reviews may be helpful regarding
details on other aspects of the biology of ANP [6—12].
Synthesis and secretion
Figure 1 shows that the prepro-ANP gene consists of three
exons and two intervening introns [6, 12]. In the human,
prepro-ANP is a single copy gene located on the short arm of
chromosome 1. Transcription of this gene proceeds at a high
rate and accounts for 1% to 3% of all messenger RNA (mRNA)
in the cardiac atria, more than for any other atrial protein.
Expression of the ANP gene can be affected both by glucocor-
ticoid and thyroid hormones [13, 14].
The prepro-ANP molecule contains 149 to 153 amino acids
(151 in humans, 15 kilodaltons) and includes a hydrophobic
signal peptide that allows proper intracellular trafficking and
processing of the pro-ANP molecule. The degree of homology
for pro-ANP in the human, rat, mouse, dog, and rabbit exceeds
70% [61. Following removal of the signal peptide (and in some
species, a carboxy-terminal arginine-arginine dipeptide), the
126 amino acid pro-ANP is formed and stored within atrial
granules [9]. Closely coincident with the exocytotic fusion of
the atrial granule with the plasma membrane, pro-ANP is
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cleaved by a specific protease into two products that enter the
circulation, an N-terminal fragment of unknown biologic impor-
tance, and ANP.
A 28 amino acid (3 kilodaltons) molecule, ANP is phyloge-
netically highly conserved, differing by only one amino acid in
humans and rodents. Peptides of slightly different lengths (24,
25, and 31 amino acids) occur in the central nervous system and
testis, indicating alternate post-translational processing modes
[6, 91. A structurally similar natriuretic peptide of 26 amino
acids is also produced in porcine brain [15].
The major site of ANP sythesis is in myocytes of the cardiac
atria, greater on the right than on the left. All myocytes within
the atria synthesize ANP. The ventricles contain ANP mRNA
in small quantity, predominantly in cells of the subendocardium
[6]. Ventricular expression is normally only 1% to 2% that of
the atria in adults but is higher in utero, falling soon after birth
[12, 16]. Ventricular expression increases if the heart is sub-
jected to increased pressure, to volume overload, or to both
[17]. Emergence of ventricular ANP expression in the hyper-
trophied heart therefore recapitulates the embryonic pattern.
Other extra-atrial tissues express ANP mRNA at low levels.
In the brain, ANP-containing neurons are especially prominent
along the anterolateral border of the third ventricle (A3V3
region) and within the hypothalamus, areas importantly in-
volved in the central neural regulation of cardiovascular func-
tion [18]. Less ANP expression is also found in the pons, limbic
system, cerebral cortex, and pituitary as well as in the periph-
eral autonomic ganglia [6, 18]. In the lung, ANP has been
identified in ovoid cells of the peripheral alveolar walls. A high
level of ANP mRNA is found in the adventitial area of the aortic
arch around the bifurcation of the major cephalic vessels.
Although no function has yet been demonstrated, these brain,
lung, and aortic arch sites of ANP synthesis suggest the
intriguing possibilities of local participation of ANP in control
of central cardiovascular regulation, pulmonary function, and
baroreceptor activity, respectively.
The major stimulus for ANP secretion by the atrial myocyte
is stretch [19]. Conditions that increase cardiac pre-load and/or
afterload and hence right and/or left atrial stretch are associated
with increased ANP secretion. Circulating ANP levels increase
modestly with exercise and with an increase in dietary sodium.
Larger increases in ANP levels can be observed during acute
and chronic extracellular volume overload, as in patients with
primary aldosteronism, the syndrome of inappropriate secre-
tion of antidiuretic hormone, and renal failure prior to dialysis
and ultrafiltration [11]. The level of ANP is unchanged in
patients with uncomplicated essential hypertension [20]. The
most marked increase in ANP occurs in patients with acute
hypertension, congestive heart failure, or valvular heart disease
[7, 11, 2 1—23]. In general, there is excellent correlation of
circulating ANP concentration with either the level of right
atrial pressure, left atrial pressure, or with both [21—23].
A second regulator of ANP secretion, independent of atrial
pressure or tension, is heart rate [24]. In paroxysmal atrial
tachycardia, ANP secretion can be very high, even without
substantial elevation of atrial pressures [25, 26]. Other factors
shown directly or indirectly (via increased atrial tension) to
cause ANP release in vitro include alpha- and beta-agonists,
cholinergic agents, phorbol esters, calcium ionophores, and,
most recently, endothelin [27, 28], although the physiologic
significance of these stimuli is unknown. To date, no clinical
syndromes of primary excess or deficiency of ANP have been
described.
Receptors and intracellular signal transduction
As Figure 2 shows, ANP released from the heart can bind to
one of two high-affinity cell surface receptors with an apparent
dissociation constant (Kd) of approximately 10— 'M.
The overwhelming majority, more than 99% of the receptors
for ANP in the kidney and vascular smooth muscle, are
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Fig. 1. Molecular and cellular biochemistry of ANP production from
prepro-ANP gene.
Fig. 2. ANP released by stretch or rate binds either to a clearance
receptor or to a biologic receptor, which forms cyclic GMP (cGMP)
that then induces vasodilation, neuroendocrine actions, and glomerular
hyperfiltration and inhibition of sodium transport in the inner medullaiy
collecting duct.
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clearance receptors [29, 301. The ANP clearance receptor is a
molecule of 496 amino acids (56 kilodaltons) [311. Most of the
molecule is extracellular, with short transmembrane (23 amino
acids) and cytoplasmic (37 amino acids) domains. These recep-
tors bind ANP and remove it from the circulation. Simple
removal of a substance from the circulation also has been
suggested as a primary function of several other receptors,
including those for low-density lipoproteins, transferrin, asialo-
glycoproteins, and insulin-like growth factor II (IGF-II)/man-
nose 6-phosphate [29, 30]. The abundance of ANP clearance
receptors accounts for the short half-life of 3 minutes for
circulating ANP. The clearance receptors are not coupled to
any known intracellular signal transduction system, nor have
they been demonstrated to mediate any physiologic effect.
The structure of the biologic receptor for ANP in the rat and
human has been elucidated recently [32—34]. It contains 1029
(human) or 1057 (rat) amino acids and has an estimated molec-
ular weight of approximately 115 kilodaltons. This receptor is
the prototype of a new receptor class: the same polypeptide not
only binds a hormone but itself also catalyzes formation of an
intracellular second messenger [34].
The ANP biologic receptor has an extracellular domain of 441
amino acids responsible for ANP binding that bears significant
homology (33%) with the binding region of the ANP clearance
receptor. There is a single, short membrane-spanning region of
21 amino acids preceding the remaining 568 amino acid cyto-
plasmic domain. Interestingly, the proximal portion of this
cytoplasmic domain has substantial homology (3 1%) with the
tyrosine kinase portion of other receptors, such as that for
platelet-derived growth factor [32—34]. The function of tyrosine
kinase activity in this and other receptors is currently unknown.
The distal, carboxy-terminal cytoplasmic portion of the ANP
biologic receptor catalyzes the conversion of GTP to 3',S'-
cyclic guanosine monophosphate (cGMP) and bears significant
homology (42%) to soluble guanylate cyclases [32—34]. Bio-
chemical evidence previously had suggested that the ANP
receptor and membrane-bound guanylate cyclase were insepa-
rable [9].
The bifunctional nature of the biologic ANP receptor allows
for direct generation of the second messenger for ANP's
biologic actions, cGMP [35, 36]. Production of cGMP in cells in
response to ANP receptor occupancy can be massive, greater
than 1000-fold above baseline. Other second messenger sys-
tems are sometimes affected by ANP, such as reduction in
cAMP generation, but without known physiologic or functional
correlation. Atrial natriuretic peptide is a unique peptide hor-
mone in its use of cGMP as its second messenger [37, 38].
After being produced in response to ANP, cGMP activates a
cGMP-dependent protein kinase. This kinase induces dilation in
vascular smooth muscle and mesangial cells, at least in part, by
attenuating the rise in intracellular calcium induced by any
vasoconstrictor (for example, angiotensin II, vasopressin, nor-
epinephrine) [39, 40], perhaps by activating a calcium-ATPase
[41]. Even when intracellular calcium rises, cGMP blocks the
subsequent contractile response by preventing phosphorylation
of the myosin light chain [42]. The functional effects of ANP are
similar to those induced by endothelium-derived relaxing factor
and nitrovasodilating drugs, which also use cGMP as a final
common pathway for signal transduction [39]. In granular cells
of the juxtaglomerular apparatus, cGMP inhibits renin release
ANP Receptor ÷
cGMP Generation ÷ — — +
Functional Effect ÷ +
Fig. 3. Nephron sites of receptors, cGMP generation, and functional
effects for ANP.
[43]. In cells of the medullary collecting duct, cGMP acts to
close a sodium channel [44].
Cardiovascular and neuroendocrine actions
Atrial natriuretic peptide can relax smooth muscle that has
been contracted by any vasoconstrictor [37, 39]. This endothe-
hum-independent, cGMP-mediated action diminishes preload
by dilating veins and afterload by relaxing arteriolar resistance
vessels and thus lowers blood pressure. No direct myocardial
effect of ANP has been described. Hematocrit increases pre-
dictably and rapidly because of transudation of fluid from the
vascular space that is driven by increased capillary hydraulic
conductivity [451; such intravascular fluid loss contributes to
ANP's hypotensive effect.
Atrial natriuretic peptide decreases biosynthesis and release
of renin, aldosterone, and vasopressin [6, 8, 10, 43]. These
effects on the hormone-producing cells sometimes are demon-
strable within the time frame of acute infusions of ANP. It
diminishes sympathetic discharge directly [46], although sec-
ondary, reflex sympathetic activation occurs due to hypoten-
sion. Changes in total peripheral vascular resistance are there-
fore variable. Reflex tachycardia in response to ANP-induced
hypotension is often subnormal or absent.
Mechanism of natriuretic action
The glomerulus is rich in ANP receptors (Fig. 3) [47—54].
Marked cGMP generation occurs in response to ANP [35, 38,
55—59], and ANP can profoundly augment GFR [35, 60—68]. The
principal mechanism by which ANP increases GFR is by raising
the glomerular hydraulic pressure [62—64, 69]. By dilating the
afferent arteriole [62, 63, 70—72] and constricting the efferent
arteriole [62, 70], ANP thereby maintains total renal vascular
resistance relatively constant. Probably by relaxing mesangial
cells [73], ANP also increases the glomerular capillary ultrafil-
tration coefficient (Kf) [62, 63]. Glomerular hyperfiltration is
sustained because ANP inhibits tubuloglomerular feedback [64,
74].
Although a brief and mild increase in total renal blood flow
Glomerulus Proximal
tubule
Loop Collecting
duct
÷
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can occur during the initial 2 minutes following onset of
continuous ANP administration [68, 75], the glomerular hyper-
filtration and natriuresis are sustained despite return of renal
blood flow to a control level [68, 75—77]. A unique hormone,
ANP can increase GFR above normal without altering total
renal blood flow; consequently, filtration fraction rises. This
hormone also does not systematically affect the relative corti-
callmedullary distribution of blood flow, variably reported as
decreased [78, 79], unaltered [76, 77], and increased [80]. The
functional significance of redistribution of renal blood flow is
controversial even when documented.
The proximal nephron lacks ANP receptors, has no mem-
brane-bound guanylate cyclase, and does not generate cGMP in
response to ANP [35, 48—59]. Consistent with this lack of
biochemical signaling capacity, 9 functional studies using in-
vivo and in-vitro microperfusion [81—84] or free-flow micro-
puncture techniques [60, 61, 65, 66, 85] in the rat or rabbit have
failed to find any effect of ANP on transepithelial sodium,
bicarbonate, and chloride transport in S, S,, and S3 subseg-
ments of proximal convoluted and straight tubules. In the
proximal tubule, ANP also does not alter phosphate absorption
or organic acid secretion [81, 84, 86]. A study that employed the
problematic technique of shrinking split droplets suggested that
ANP affected proximal sodium transport under the condition of
prestimulation by angiotensin II [87], but this observation could
not be confirmed by the more reliable technique of in-vivo
microperfusion [831.
Just as in the proximal tubule, cells of nephron segments
within the loop of Henle lack ANP receptors [49] and respond
with little cGMP generation when ANP is administered [55, 56,
58, 59]. In-vivo and in-vitro microperfusion studies have dis-
closed no effect of ANP on sodium chloride transport in the
cortical or medullary thick ascending limb in the rat and rabbit
[88, 89]. A small, indirect effect on solute and water transport in
the thin limbs of Henle occurs [90] when ANP diminishes
medullary solute concentration consequent to high luminal flow
rate and vasa recta hydraulic pressure [91].
A relatively low expression of ANP receptors and generation
of cGMP exist in the cortical collecting duct [49, 56, 59]. In the
in-vitro microperfused cortical collecting duct, ANP inhibits
sodium chloride and vasopressin-stimulated water absorption,
and these effects are mediated by cGMP [92, 93]. The highest
density of ANP receptors and briskest cGMP generation in the
collecting system are found in the inner medullary collecting
duct [48, 50—54, 56, 59]. In cells of this segment in culture, ANP
depresses sodium uptake [94] by means of cGMP-mediated
inhibition of a membrane sodium channel [44]. But ANP does
not change sodium chloride permeability of the tubule [95]. In
this segment, ANP also inhibits vasopressin-stimulated osmotic
water permeability [96]. Micropuncture and microcatheteriza-
tion techniques have confirmed in vivo that ANP reduces
transepithelial sodium and water transport by the inner medul-
lary and the papillary collecting ducts [85, 97—99].
Atrial natriuretic peptide also has indirect effects that result
from altered neuroendocrine function. The peptide inhibits
biosynthesis of both renin and aldosterone [68, 75] and antag-
onizes the action of angiotensin II on cells bearing receptors for
both hormones [37]. Also, ANP decreases the activity of the
sympathetic nervous system [46] and inhibits vasopressin re-
lease and action [92, 96]. These neuroendocrine-mediated ef-
Table 1. Relative importance of GFR versus tubular transport in
mediating the natriuresis of ANP
GFR
Collecting duct
NaCI transport UNV
ANP t
ANP with aortic constriction -*
Amiloride -* I -*
Glucagon C * C
fects of ANP potentially are additive to direct effects and are
capable of altering transport along the entire length of the
nephron: in the glomerulus (angiotensin II, nerve activity, and
vasopressin), proximal tubule (angiotensin II and nerve activi-
ty), loop of Henle (vasopressin and nerve activity), and collect-
ing tubule (aldosterone, vasopressin, and nerve activity).
As noted, the primary sites of action of ANP are the
beginning and end of the nephron: the glomerulus and the inner
medullary collecting duct. Substantial controversy persists re-
garding the relative importance of these two effects. The
possibility that an ANP-induced rise in GFR could, by itself,
result in a natriuresis had seemed untenable because a compa-
rable rise in GFR induced by protein feeding causes only a
minor change in urinary sodium excretion [100]. It is now
known, however, that dietary protein is a potent stimulus for
renin secretion [101], which could independently promote anti-
natriuresis. Thus, given the unusual ability of ANP to markedly
augment GFR, the possibility remains that the magnitude of
urinary sodium excretion observed can be due simply to the
increased quantity of sodium filtered [47, 61, 65, 67].
Based on in-vivo microperfusion and micropuncture obser-
vations, load dependence of sodium chloride transport in the
proximal nephron (as distinguished from load dependence of
sodium bicarbonate transport) is known to be very poor; that is,
there is little or no proximal glomerulotubular balance for
sodium chloride [66, 102]. When GFR acutely rises above
normal, most of the increment in filtered sodium chloride
escapes reabsorption and passes out of the proximal tubule [66].
Although load dependency of transport is better in the loop, the
fraction of sodium chloride reabsorbed in the loop of Henle and
the distal nephron actually falls as delivery increases [103, 104].
Indeed, only 10% or so of the increment in sodium chloride
emerging from the proximal tubule needs to escape absorption
by the distal nephron to fully account for the magnitude of
natriuresis and chloruresis observed following ANP administra-
tion. Thus, changes in GFR in the setting of inherently imper-
fect load-dependent transport kinetics of sodium chloride reab-
sorption in the nephron could easily explain a concomitant
alteration in urinary sodium excretion.
Several strategies have been employed to evaluate the rela-
tive potencies of glomerular versus tubular actions of ANP, as
summarized in Table 1. First, GFR has been maintained con-
stant during ANP administration, by reducing renal perfusion
pressure using aortic constriction [61, 105—107]. Although still
inhibiting sodium transport in the collecting duct, ANP exerts
very little or no change in urinary sodium excretion if GFR does
not rise. Second, the degree of natriuresis induced by ANP has
been compared with that of a diuretic such as amiloride, which
does not change GFR but which mimics ANP's ability to inhibit
the medullary collecting duct sodium channel [94]. Amiloride is
1152 Nephrologv Forum: Atrial natriuretic peptide
impotent in effecting a diuresis or natriuresis, and amiloride
pretreatment does not alter the natriuresis induced by ANP
[1081. Third, the natriuretic potency of ANP has been compared
with that of glucagon. A pharmacologic concentration of giuca-
gon raises GFR but does not inhibit (it may even stimulate)
sodium transport in the collecting duct. When comparable acute
glomerular hyperfiltration was induced by ANP or by glucagon,
the resulting natriuresis was similar [1091.
These observations suggest that ANP achieves a natriuresis
primarily by increasing GFR. The impact of inhibiting sodium
transport in the inner medullary collecting duct is minor com-
pared with the changes in renal sodium handling that occur
when ANP augments filtered sodium load. Some studies have
reported a natiuresis following ANP administration without
demonstrable change in GFR [67], but these reports are difficult
to interpret. It is often impossible to measure GFR with
sufficient accuracy to detect a small change, especially under
dynamic conditions of rapidly fluctuating renal hemodynamics
and urine flow rate. In general, even these studies demonstrate
a directionally upward trend in GFR when ANP is administered
[671. Finally, I should mention that a unique attribute of ANP as
a diuretic, because of its exceptional ability to raise GFR, is that
it corrects rather than creates acid-base disorders. For instance,
in the setting of chronic metabolic alkalosis, administration of
ANP induces bicarbonaturia and corrects the alkalemia [110,
1111.
Physiologic significance
The studies I have summarized thus far showing ANP's
potent effects on cardiovascular, endocrine, and renal function
generally have employed pharmacologic concentrations of the
hormone. The functional role of ANP when present in physio-
logic concentrations is still far from clarified. The vast number
of reports correlating ANP levels with renal sodium excretory
response under various physiologic maneuvers or pathophysi-
ologic conditions leave begging the crucial question of causal-
ity. Uncertainty persists regarding the critical consideration of
whether ANP within the physiologic concentration range has an
important impact on adjustment of urinary sodium excretion.
The analysis of ANP's significance in cardiovascular homeo-
stasis has been hampered by the lack of an effective inhibitor of
ANP synthesis or of ANP binding to its biologic receptor. In
lieu of an antagonist, investigators have taken other, less
persuasive approaches. First, physiologic maneuvers have been
performed with the atrial appendage or the entire atrium re-
moved to diminish ANP production [7]. Problems with this
ablation approach are obvious: normality of cardiac perfor-
mance cannot be assured, and other cardiovascular reflexes
initiated by the atria, notably via cardiac nerves, are simulta-
neously eliminated. Second, anti-ANP antibodies have been
used to eliminate the participation of ANP under various
conditions [7]. This tactic is also problematic because of non-
specific effects of the antibody and/or of the antigen-antibody
complex. Third, autoimmunity against ANP has been induced
to allow studies of chronically ANP-deficient animals [1121. The
conclusion reached with this approach was that ANP plays little
role in physiologic conditions, in the renal response to change in
dietary sodium, or in mineralocorticoid escape, but that it helps
defend against massive, acute volume expansion [112].
An alternative, admittedly highly inferential, strategy has
been to analyze the independent natriuretic effect of ANP
following its intravenous infusion in normal individuals, achiev-
ing circulating ANP concentrations that match endogenous
levels under physiologic or pathophysiologic conditions. The
reference data against which such infusion studies must be
judged are the ANP concentrations under normal and disease
conditions. In most laboratories, the endogenous circulating
ANP concentration in normal, euvolemic humans is approxi-
mately 10—70 pg/mI (3—25 pM). Physiologic changes in cardio-
vascular status usually are not associated with marked changes
in atrial stretch. Therefore, variation in dietary sodium chloride
intake [113—117], posture [11, 117], exercise [118], and central
volume expansion due to water immersion [119—122] or follow-
ing escape from sustained mineraiocorticoid administration
[123—125] cause only a modest, two- to threefold change in the
plasma ANP concentration. The maximum ANP concentration
elicited by these physiologic maneuvers is usually less than 100
pg/mi.
Figure 4 illustrates a distillation of results from 15 studies in
humans in which ANP was infused continuously for a short
duration (0.3 to 6.0 hours) [126—140]. Sustained infusion of 10
ng/kg/min elevates the plasma ANP concentration to the highest
limit of the physiologic concentration range, to approximately
100 pg/mi, and only modestly raises the urinary sodium excre-
tion rate, usually less than 30% above the basal level. Concom-
itant hemodynamic changes induced by ANP, such as dimin-
ished preload and cardiac output sometimes have been
documented, and these alterations could counteract the direct
natriuretic effects of the hormone [140].
Table 2 compares the minor increase in renal sodium excre-
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Fig. 4. Effects of progressive ANP infusion in normal humans on
urinary sodium excretion and on circulating plasma ANP concentra-
tion. (Data collated from Refs. 126—140.)
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Table 2. Changes in plasma ANP concentration and natriuresis
induced by physiologic maneuvers compared with those by ANP
infusion in humans
[ANP]a
(pg/,n1)
UNaVb
(,uEq/min)
Physiologic maneuver
Dietary NaC1 (l0O—350 mEq/day)C 25 (25—*50) 175 (70—245)
Mineralocorticoid escaped 15 (25—*40) 80 (I 20—.200)
Immersione 20 (25—*45) 200 (I00—*300)
Infusion
3—5 ng/kg/min 25 (25—50) 20 (160—*180)
a [ANP] refers to change in plasma ANP concentrations induced by
the maneuver.
b UNaV refers to change in urinary sodium excretion induced by the
maneuver.
C From Refs. 113—117.
d From Refs. 123—125.
From Refs. 119—122.
From Refs. 126—140.
tion associated with a physiologic level of ANP produced by
infusion of exogenous ANP with the natriuresis that occurs
during physiologic conditions. When plasma ANP is increased
about 25 pg/mI by exogenous administration (3—5 ng/kg/min
ANP infusion rate in Fig. 4), urinary sodium excretion rises by
only approximately 20 Eq/min. This small natriuretic response
is only about 10% to 25% of that observed when a comparable
change in ANP concentration is induced during alteration in
dietary sodium intake from 100 to 350 mEq/day [113—117],
during mineralocorticoid escape [123—1251, and during head-out
water immersion or lower-body positive pressure [119—1221.
In contrast, during pathophysiologic conditions associated
with a marked increase in atrial pressure (such as congestive
heart failure) or heart rate (for example, paroxysmal atrial
tachycardia), the circulating plasma ANP concentration sub-
stantially increases, although the level is usually no higher than
400 to 500 pg/ml [21—23, 141—144]. As Figure 4 shows, with
higher ANP infusion rates that duplicate the ANP concentra-
tions that obtain during pathophysiologic conditions, the natri-
uretic response is reproducibly larger, increasing two- to three-
fold.
The inference, based on analysis of infusion studies, that
ANP possesses only modest biologic potency within the phys-
iologic range, should be considered tentative (Fig. 4, Table 2).
Interpretation is hampered because basal conditions and dy-
namic neurohumoral concomitants differ depending on the
maneuvers employed. With these caveats, however, the con-
clusion emerging from recent studies is that ANP modulates
urinary sodium excretion under physiologic conditions, but that
its overall effect is minor. Much more marked renal effects can
be attibuted to the renin-angiotensin-aldosterone and sympa-
thetic nervous system activities, which change severalfold
under the same physiologic maneuvers listed in Table 2. Under
pathophysiologic conditions such as heart failure, when the
renin-angiotensin-aldosterone, sympathetic nervous, and ANP
systems all are simultaneously activated, ANP may serve to
moderate the more dominant antinatriuretic forces (Fig. 4). For
instance, it is plausible that the intensity of the antinatriuresis
attributable to high levels of renin-angiotensin-aldosterone and
renal nerve activities might be lessened by a concomitantly high
ANP level. Sometimes, however, the antinatriuretic systems
activated during congestive heart failure are so strong that even
a very high concentration of ANP is ineffective in preventing
urinary sodium from falling to near zero.
Thus, ANP's potency under physiologic conditions is rela-
tively limited, and ANP appears to occupy third place in
importance behind the renin-angiotensin-aldosterone and sym-
pathetic nervous systems in regulating extracellular volume. In
general, changes in ANP concentration only partially explain
changes in saliuretic responses not attributed to the renin-
angiotensin-aldosterone and sympathetic nervous systems; the
search for other natriuretic substances is by no means ended
[5].
The physiologic role of ANP may be elucidated in future
studies by quantifying urinary cGMP excretion. Cyclic GMP,
produced in the glomerulus by ANP, preferentially enters the
glomerular ultrafiltrate, undergoes neither net reabsorption nor
secretion by the nephron, and is quantitatively excreted in the
urine (Fig. 5, left). Urinary cGMP is therefore glomerulogenous
and specifically reflects ANP's action [35, 38, 145]. Because the
magnitude of urinary cGMP is proportional to the natriuresis
induced by ANP (Fig. 5, right), urinary cGMP can be used as an
index of ANP activity, even when other neurohumoral factors
influence renal function [38, 145]. Urinary cGMP therefore can
be quite useful for evaluating the role of ANP when there is
apparent resistance to the actions of ANP, that is, during
pathophysiologic states associated with complex perturbation
of cardiovascular control [119, 120, 144, 146].
Therapeutic perspectives
Whether or not ANP is an important hormone in day-to-day
extracellular volume homeostasis, its potency as a pharmaco-
logic agent in altering cardiovascular and renal function makes
it an attractive candidate for treating patients with hyperten-
sion, excessive cardiac pre- and afterload, or glomerular hypo-
filtration and antinatriuresis. Unfortunately, being a peptide, it
must be given intravenously. So far, however, the overall
benefit from short-term, parenteral administration of ANP in
diseases associated with edema has been variable and relatively
unimpressive, often limited by hypotension.
In patients with congestive heart failure, as in the patient
presented in this Forum, infusion of a large amount of ANP
temporarily augments cardiac output but results in little natri-
uresis [141—144]. Even in pharmacologic concentrations, ANP
lacks the potency to substantially overcome the more potent
renal salt-retaining effects of the renin-angiotensin-aldosterone
and sympathetic nervous systems activated in congestive heart
failure. In patients with the nephrotic syndrome, ANP infusion
augments both sodium and protein excretion in parallel with a
reduction in blood pressure [147]. Variable short-term benefits
also have been reported in patients with hypertension [148],
pulmonary hypertension [149], and cirrhosis [150].
Given its powerful ability to augment glomerular filtration
rate, an exciting therapeutic prospect for ANP is in reversal of
acute renal failure. In various models of acute renal failure in
the rat, including the postischemic [151—153], norepinephnne
[154], and uranyl-nitrate [155] models, ANP administered after
the hemodynamic insult partially restores GFR. Assessment of
the efficacy of ANP in clinical states of acute renal failure in
humans is obviously needed.
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Fig. 5. Left panel shows paired measurements of relative cGMP delivery co,npared with inulin in Bowman's space, the end-proxi,nal tubule, and
urine following ANP administration in the rat. The dashed line represents fractional delivery of unity, which would occur if cGMP, like inulin, were
filtered but neither produced by the glomerulus nor reabsorbed or secreted in the tubules. The right panel depicts sodium excretion rate as a
function of urinary cGMP excretion rate during graded infusion of ANP in rats. (Reprinted with permission from Refs. 35 and 145.)
Questions and answers
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center, Boston,
Massachusetts): Given that ANP is an "old" hormone from the
evolutionary standpoint, what important function does it serve
for lower animals?
DR. COGAN: ANP is indeed an ancient hormone, with phys-
iologic effects documented in sharks and fish [156—158]. Its
direct and indirect actions on salt transport in these species
suggest that ANP might be important in controlling plasma
volume, especially in response to alterations in environmental
salinity [158].
DR. KASSIRER: Can you speculate on why we produce so
much ANP and yet degrade most of it?
DR. COGAN: The great abundance of clearance receptors
compared with biologic receptors for ANP undoubtedly con-
tributes to the high metabolic clearance rate and very short
half-life (3 mm) of the hormone. The rapid degradation of most
of the secreted ANP may provide a peripheral hormonal buff-
ering system [29—31].
DR. JOHN T. HARRTNGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I am struck by
the fact that virtually 99% of ANP receptors are clearance
receptors. Are there other peptides that have such a high
percentage? Does this peculiar distribution tell us anything
about the importance of ANP?
DR. COGAN: The rapid and efficient internalization and sub-
sequent degradation of ligand by the clearance receptor for
ANP is similar to the function of receptors for low-density
lipoproteins, transferrin, asialoglycoproteins, and insulin-like
growth factor II (IGF-II)/mannose 6-phosphate [29, 30]. Be-
sides reducing the plasma half-life of these substances, it
sometimes has been difficult to identify another biologic conse-
quence for such a receptor. For instance, the physiologic
impact of the binding and internalization of IGF-II with the
IGF-II receptor is currently unknown [159].
DR. NIcoLAos E. MAmAs (Chief, Division of Nephrology,
New England Medical Center): You suggested that the biologic
effectiveness of ANP might be more pronounced in pathophys-
iologic conditions, such as congestive heart failure, compared
with physiologic circumstances. Yet, in congestive heart fail-
ure, little sodium might be found in the urine, and the persisting
antinatriuresis often defies even pharmacologic concentrations
of ANP. What, then, is the evidence that ANP plays an
important role in such conditions?
DR. COGAN: The proposed functional role of ANP in conges-
tive heart failure, to moderate the more dominant antinatri-
uretic effects of the renin-angiotensin-aldosterone and sympa-
thetic nervous systems, is largely speculative at present. Based
on data summarized in Figure 4, it is reasonable to presume that
antinatriuresis during congestive heart failure might be even
more intense (if it is not already maximal) were ANP not
present. Support for the thesis that ANP is capable of affecting
renal function comes from the observation that urinary cGMP
excretion rises following infusion of a pharmacologic dose of
ANP in patients with congestive heart failure [144]. The small
subsequent increase in urinary sodium excretion attests to the
relative primacy of the neurohumoral forces that oppose ANP.
DR. KASSIRER: Much time and energy has been spent on
explaining the phenomenon of changes in sodium excretion in
the absence of a change in GFR or in the renin-aldosterone-
angiotensin system. Now that we know that this volume-related
phenomenon is not a function of ANP, are we any closer to
understanding the mechanism?
DR. COGAN: The search for a factor that controls renal
sodium handling independent of GFR and of the renin-angio-
tensin-aldosterone system dates back many decades, at least to
the studies of de Wardener and others [see 3, 5]. This "third
factor" has eluded isolation and structural definition, but it
often appears to be associated with inhibition of Na/K-
ATPase activity. Atrial natriuretic peptide has no effect on the
Na/K-ATPase and clearly does not fully explain the phenom-
ena attributed to the long-sought "third factor." The search
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therefore continues for other hormones or factors that regulate
renal sodium handling.
DR. MICHAEL MADAIO (Nephrolo gist, New England Medical
Center): Have antibodies been produced that distinguish be-
tween the two ANP receptors?
DR. COGAN: With the recent purification and sequencing of
the ANP receptors, it soon should be possible to produce
antibodies selective against the heterologous extracellular do-
mains of each. So far, analogues derived from molecular
modification of ANP itself have shown inhibitory activity
against the clearance receptor only [29, 30].
DR. ANDREW LEVEY (Nephrologist, New England Medical
Center): You speculated that ANF is not completely responsi-
ble for the natriuresis observed during dietary sodium chloride
ingestion, mineralocorticoid escape, and head-out water immer-
sion. Are the elevated levels of ANF observed in these condi-
tions sufficient to increase GFR? If so, can we conclude that
small elevations in GFR are not responsible for the natriuresis?
DR. COGAN: The rise in circulating ANP concentration in the
conditions mentioned probably contributes to a portion of the
observed changes in sodium excretion (Table 2). The available
evidence suggests that ANP would participate in these alter-
ations in renal sodium handling predominantly by augmenting
GFR (Table I). However, the magnitude of an ANP-induced
change in GFR expected under these conditions would be very
small and not reliably detected by current methods. Indeed, the
accuracy of GFR measurement in the best of hands is usually no
better than 5%. Change in GFR would often be expected to
be no more than 5%. Thus, the increment in sodium filtration
that would completely explain the portion of the natriuretic
response attributable to ANP would be undetectable by stan-
dard clearance techniques. The experience with ANP raises the
possibility that small, sometimes unmeasurable, changes in
GFR can affect renal sodium excretion to a physiologically
significant degree.
DR. MADIAS: Is ANP receptor density regulated by changes
in plasma ANP levels?
DR. COGAN: Total ANP receptor density correlates inversely
with plasma ANP concentrations [160]. Differentiation between
regulation of the biologic and clearance receptors has not yet
been performed.
DR. HARRINGTON: You stated that ANP is a generalized
vasodilator. Yet within the kidney, although ANP does cause
afferent arteriolar vasodilation, ANP apparently also causes
efferent vasoconstriction. What accounts for this latter, para-
doxical effect?
DR. COGAN: The mechanism by which ANP increases ef-
ferent arteriolar tone in most [62, 70] although not all [72]
microvascular studies and increases total vascular resistance in
the isolated perfused kidney [67] has yet to be explained. The
sparing of the efferent arteriole from ANP's vasodilatory effects
might be due to a lack of biologic receptors on this vascular
element. The vasoconstriction could be caused by a direct
myogenic or indirect neurohumoral reflex, but the mediator of
this anomalous response has not been elucidated.
DR. HARRINGTON: Two questions. First, could you discuss
the interaction of angiotensin II and ANP? Second, do angio-
tensin converting enzyme inhibitors have an effect on ANP?
DR. COGAN: With regard to circulating hormone levels, a
primary rise in angiotensin II that increased blood pressure
would augment ANP release. Similarly, a primary rise in ANP
that diminished blood pressure would increase the renin level
and hence angiotensin II generation. With regard to hormonal
interaction in regulating renal sodium handling, it is obvious
that angiotensin II, as a powerful antinatriuretic substance, and
ANP, as a natriuretic agent, attenuate the actions of each other.
However, one should not assume that these hormones neces-
sarily antogonize each other at similar nephron sites or that they
act oppositely on the same transport mechanisms. For instance,
when angiotensin II and ANP biologic receptors exist on the
same cell, such as the mesangial cell, ANP directly antagonizes
the biochemical and physiologic effects of angiotensin II [371. In
contrast, when a receptor-signaling-transport system is present
for one but not the other hormone on a cell, as there is for
angiotensin II but not ANP in the proximal tubule [83], the
effects of one hormone are not directly influenced by the other.
Summation of the effects of both hormones along the entire
nephron length result from both interactions localized at the
same domain as well as anatomically separate changes in
sodium transport. Drugs or maneuvers that decrease the activ-
ity of one of the hormones therefore tends to augment the renal
action of the other.
DR. JAMES STROM (Chief, Division of Nephrology, St. Eliz-
abeth's Hospital, Brighton, Massachusetts): An editorial in the
New England Journal of Medicine by Gordon Williams in 1986
alluded to the possible role of ANP in suppressing renin and
aldosterone secretion in the syndrome of hyporeninemic hy-
poaldosteronism [1621. Have there been further developments
in this regard?
DR. COGAN: Through its generation of intracellular cGMP,
ANP decreases renin production by the granular cells of the
juxtaglomerular apparatus [43]. In cells of the adrenal zona
glomerulosa, ANP also directly depresses aldosterone biosyn-
thesis [161]. In short-term studies, ANP tends to decrease both
renin and aldosterone levels [5—8, 10, 11, 67, 68, 128, 133—135,
138, 139]. The inhibition is usually short-lived, however, and
often counteracted by concomitant hemodynamic changes [7,
140]. Neither circulating ANP nor urinary cGMP levels have
been reported to be elevated in hyporeninemic hypoaldoster-
onism.
DR. KASSIRER: Is ANP useful in patients resistant to diuret-
ics?
DR. COGAN: I believe ANP belongs to a special class of
diuretics, capable of augmenting urinary sodium excretion
primarily by inducing glomerular hyperfiltration. As such, it
should be additive, indeed synergistic, with conventional di-
uretics that are tubular transport inhibitors. Given the limita-
tions that ANP must be given intravenously (because it is a
protein) and should be administered in a highly monitored
intensive care setting (because of its profound hemodynamic
effect), it should be quite useful in the setting of resistance to
conventional diuretics. Its ability to effect a natriuresis and
diuresis while increasing GFR without creating acid-base dis-
turbances is an additional advantage of therapy.
DR. MADAIO: If ANP levels are extremely high in these
patients, why should more ANP be effective?
DR. COGAN: Despite an elevated ANP level in congestive
heart failure (400—500 pg/mI), pharmacologic infusion of ANP
can be used to achieve an even higher circulating concentration
(2000—3000 pg/mi), which is sometimes sufficient to induce a
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modest natriuretic response [141—144]. This observation sug-
gests that the high circulating ANP concentrations in patho-
physiologic states are submaximal with regard to physiologic
response.
DR. MADAI0: Can you explain the mechanism of the phar-
macologic effect?
DR. COGAN: The pharmacologic effects of ANP are simply
exaggerations of the cGMP-mediated responses that are ob-
served with lower, physiologic ANP concentrations [145].
DR. HARRINGTON: Could you describe the sequential
changes in ANP during pregnancy? Second, do these changes
contribute to salt balance in pregnancy?
DR. COGAN: Circulating ANP tends to rise slightly during
pregnancy, presumably as a response to the hypervolemia
[163]. Pregnancy-induced hypertension and preeclampsia de-
velop despite even higher ANP levels [1631.
DR. MADIAS: Is the affinity of ANP for its receptor different
among various organs (for example, vasculature, adrenal gland,
kidney)?
DR. COGAN: The affinity of ANP for both receptors is
approximately 1O0 M, without substantial variation in various
target organs.
DR. PAUL KURTIN (Chief, Division of Pediatric Nephrology,
New England Medical Center): An elevated GFR in conjunc-
tion with an exaggerated natriuresis and chloruresis suggests an
impairment of tubuloglomerular feedback. Does ANP affect
tubuloglomerular feedback?
DR. COGAN: You are quite correct that persistence of gb-
merular hyperfiltration does imply the suppression of tubulo-
glomerular feedback. Normal lowering of both glomerular hy-
draulic pressure and glomerular filtration rate in response to an
increase in loop perfusion rate is markedly blunted when ANP
is present [64, 741.
DR. MADrAS: Could you speculate on the mechanism of the
inhibition of tubuloglomerular feedback by ANP?
DR. COGAN: It is unlikely that the mechanism by which ANP
alters tubulogbomerular feedback is by interrupting the macula
densa signal, because ANP does not alter the function of the
thick ascending limb. More probable is that ANP alters the
effector limb of the response by rendering the afferent arteriole
unresponsive to the feedback signal. It is possible that ANP
alters the coupling mechanism of the macula densa afferent
signal to the myogenic response.
Reprint requests to Dr. M. Cogan, Nephrology Section (IJIJ), VA
Medical Center, 4150 Clement Street, San Francisco, California 94121,
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